New drug trial aims to rev up immune system to fight advanced cancers
NCT ID NCT02936102
Summary
This was a first-in-human study to test the safety and find the right dose of a new immunotherapy drug called FAZ053. It was given alone and in combination with another drug, PDR001, to 154 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to see how safe the drug was and how the body processed it, while also checking for any early signs that it could help shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Ctr
New York, New York, 10065, United States
-
Novartis Investigative Site
Toronto, Ontario, M5G 2M9, Canada
-
Novartis Investigative Site
Toulouse, 31059, France
-
Novartis Investigative Site
Tel Aviv, 6423906, Israel
-
Novartis Investigative Site
Milan, MI, 20133, Italy
-
Novartis Investigative Site
Modena, MO, 41124, Italy
-
Novartis Investigative Site
Koto Ku, Tokyo, 135 8550, Japan
-
Novartis Investigative Site
Singapore, 119074, Singapore
-
Novartis Investigative Site
Seville, Andalusia, 41013, Spain
-
Novartis Investigative Site
Barcelona, Catalonia, 08035, Spain
-
Novartis Investigative Site
Taipei, 10002, Taiwan
-
UT MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.